Observational studyFrontiers in cellular and infection microbiology2026
Thrombomodulin: a potential biomarker for sepsis-associated acute kidney injury resulting from bacterial infections.
Observational study in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a temporal staging-based nomogram for 1-year mortality in sepsis-associated acute kidney injury.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-associated acute kidney injury (SA-AKI) is a common complication of sepsis. Serum creatinine is a delayed AKI marker influenced by multiple confounders and cannot reflect endothelial injury central to SA-AKI. Thrombomodulin (TM) is an endothelial biomarker linked to coagulation and inflammation, but its predictive value for SA-AKI in bacterial infection remains undefined. We aimed to evaluate the independent predictive performance of TM for SA-AKI in bacterial sepsis. Methods: This was a single-center retrospective observational study enrolling 81 patients with bacterial sepsis (37 with SA-AKI, 44 without SA-AKI) admitted to the intensive care unit of the First Affiliated Hospital of Soochow University. Blood samples were collected within 24 hours of sepsis diagnosis for TM measurement. For comparisons between two independent groups, Student's t-test was used for normally distributed variables, while Mann-Whitney U test was utilized for non-normally distributed variables. For multi-group comparisons involving normal distribution with homogeneous variance data, One-way analysis of variance with Bonferroni Results: Thrombomodulin was significantly elevated in patients with AKI compared to that in non-AKI patients, and the odds ratio for thrombomodulin was 1.17 in a multivariable logistic regression analysis. The Area under curve (AUC) value for thrombomodulin in SA-AKI was 0.81. In subgroup analysis, thrombomodulin expression was significantly higher in the vasoactive drug group. The AUC of thrombomodulin with vasopressor use was 0.70. In the group that did not utilize vasoactive drugs, the AUC of thrombomodulin in SA-AKI was 0.81. Thrombomodulin expression was significantly higher in the Continuous Renal Replacement Therapy (CRRT) group. The AUC of Thrombomodulin (TM) when CRRT was used was 0.80. In the group that did not receive CRRT, the AUC of thrombomodulin predicted by SA-AKI was 0.75. Conclusions: Thrombomodulin may be valuable in independently predicting SA-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.